Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(incorporated in Bermuda with limited liability)
(Stock Code: 431)

website: http://www.irasia.com/listco/hk/greaterchina/index.htm

COMPLETION OF DISCLOSEABLE TRANSACTION OF ACQUISITION OF ENTIRE ISSUED SHARE CAPITAL OF ACCESS CHINA GROUP LIMITED INVOLVING ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE

Reference is made to the announcement (the "Announcement") of Greater China Financial Holdings Limited (the "Company") dated 14 December 2016 in relation to the acquisition of the entire issued share capital of Access China Group Limited. Unless otherwise defined herein, terms used in this announcement shall have the same meaning as those defined in the Announcement.

COMPLETION OF THE ACQUISITION

The Board is pleased to announce that all the conditions precedent set out in the Acquisition Agreement have been fulfilled and the completion of the Acquisition took place on 22 December 2016.

Pursuant to the Acquisition Agreement, upon completion, HK\$20,000,000 has been settled in cash, and HK\$48,515,168 has been settled by allotment and issue of a total of 194,060,671 Consideration Shares to the Vendor at the Issue Price of HK\$0.25 per Share.

Upon completion, the Target Company has become a wholly-owned subsidiary of the Company and the financial results of the Target Group will be consolidated into the accounts of the Group.

By order of the Board

Greater China Financial Holdings Limited

Liu Kequan

Chairman

Hong Kong, 22 December 2016

As at the date of this announcement, the Board comprises Mr. Liu Kequan and Mr. Zhang Peidong as executive Directors; Mr. Yin Xiaoguang as non-executive Director; and Mr. Jin Bingrong, Mr. Kwan Kei Chor, Dr. Rui Mingjie, Mr. Zhou Liangyu and Dr. Lu Ziang as independent non-executive Directors.